RXi Pharmaceuticals Corp ., the Worcester biopharmaceutical company that seeks to develop drugs based on the Nobel Prize winning work of Craig Mello in gene-silencing research, announced that Noah D. Beerman has joined the... [read full story]
|
RELATED
|
|
RXi Pharmaceuticals (NASDAQ: RXII), the Worcester, MA-based developer of RNA interference drugs, said today that Noah Beerman has replaced Tod Woolf as president and CEO. Beerman, 47, was most recently chief business officer of...
News source: Business Wire RXi Pharmaceuticals Corporation , a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that Noah D....
RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that Noah read more
WORCESTER, Mass.----RXi Pharmaceuticals Corporation , a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference , today announced that Noah D.
RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that Noah D Beerman has...
RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that Noah D. Beerman has...
WORCESTER, Mass. - RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that...
News source: Business Wire RXi Pharmaceuticals Corporation , a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that Dmitry...
WORCESTER, Mass.----RXi Pharmaceuticals Corporation , a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference , today announced that Dmitry Samarsky,...
RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that Dmitry Samarsky,...
Pharmaceuticals, Medicines & Remedies, Biopharmaceuticals, Indevus Pharmaceuticals, Endo Pharmaceuticals
